PT  - JOURNAL ARTICLE
AU  - Julia Karbach
AU  - Dragan Kiselicki
AU  - Kathrin Brand
AU  - Claudia Wahle
AU  - Evgueni Sinelnikov
AU  - Dirk Gustavus
AU  - Hans Hoffmeister
AU  - Hans-Bernd Prisack
AU  - Akin Atmaca
AU  - Elke Jäger
TI  - Tumor-infiltrating lymphocytes mediate complete and durable remission in a patient with NY-ESO-1 expressing prostate cancer
AID  - 10.1136/jitc-2022-005847
DP  - 2023 Jan 01
TA  - Journal for ImmunoTherapy of Cancer
PG  - e005847
VI  - 11
IP  - 1
4099  - http://jitc.bmj.com/content/11/1/e005847.short
4100  - http://jitc.bmj.com/content/11/1/e005847.full
SO  - J Immunother Cancer2023 Jan 01; 11
AB  - Adoptive transfer of autologous tumor-specific lymphocytes represents a viable treatment method for patients with advanced malignancies. Here, we report a patient’s case with metastatic hormone-refractory New York esophageal squamous cell carcinoma 1 (NY-ESO-1) expressing prostate cancer treated with in vitro expanded tumor-infiltrating lymphocytes (TILs) in conjunction with IL-2 and immune-checkpoint blockade. Complete and durable tumor remission was observed after three TIL infusions consisting of 1.4×109, 2.0×109, and 8.0×109 T cells, respectively, lasting now for more than 3.5 years. Immunological correlates to the clinical development were the decrease of tumor-driven NY-ESO-1 serum antibody and the drop of prostate-specific antigen to <0.01 µg/L. TILs were reactive against cancer-testis antigen NY-ESO-1, individual tumor mutational proteins (eg, PRPF8, TRPS1), and the androgen receptor splice variant 12.